Skip to content
The Medicines and Healthcare products Regulatory Agency (MHRA) has published its 2024–25 Annual Report and Impact Report, showing strong progress on safety, innovation, and regulation across the UK.
The agency, which plays a vital role in safeguarding public health and supporting the UK’s life sciences sector, highlighted major improvements in performance and access to new treatments. In the last year, the MHRA has cleared all statutory backlogs, improved safety monitoring, and helped accelerate access to innovative medicines and medical technologies.
Key achievements include:
- Clearing licensing backlogs and hitting clinical trial assessment targets by March 2025
- Approving over 2,000 medicine licences—including 54 new treatments for Alzheimer’s, cancer, and rare diseases
- Launching the UK’s most significant regulatory reform of clinical trials in more than 20 years
- Reviewing over 100,000 adverse drug reaction reports and blocking 1.5 million unsafe online listings
- Piloting the world’s first “AI Airlock” for safe medical device development
- Distributing 127,000+ biological standards globally and introducing new WHO-backed pandemic standards
The MHRA also emphasised its focus on sustainability, public engagement, and international collaboration. It awarded over £7 million in research grants to support regulatory science and continued providing anonymised GP data through the Clinical Practice Research Datalink (CPRD) to support public health research.
Internally, the agency has modernised its digital infrastructure, improved cyber security, and invested in future talent through graduate schemes and apprenticeships.
Read the full story here.
